ImmunoGen, Inc. Announces Webcast of Presentation at Tucker Anthony Sutro's Health Care Conference 2001

Apr 03, 2001, 01:00 ET from ImmunoGen, Inc.

    CAMBRIDGE, Mass., April 3 /PRNewswire/ --ImmunoGen, Inc. (Nasdaq:    IMGN)
 announced today that its presentation at Tucker Anthony Sutro's Health Care
 Conference 2001 will be webcast live.  The presentation will be delivered at
 1:40 p.m. (PST) on Wednesday, April 4, 2001, from the Ritz Carlton Hotel at
 Laguna Niguel, California.  The webcast can be accessed by going to the
 "Conference Schedule" page under "News/Events" on ImmunoGen's website at
 www.immunogen.com and will be available for one month following the
 presentation.
     ImmunoGen, Inc. develops innovative biopharmaceuticals, primarily for
 cancer treatment.  The Company has created potent tumor-activated prodrugs,
 consisting of drugs coupled to monoclonal antibodies, for delivery to and
 destruction of cancer cells.  Its lead product, huC242-DM1/SB-408075 is in two
 Phase I/II clinical trials for treatment of colorectal, pancreatic and certain
 non-small-cell lung cancers.  The Company has partnerships with
 GlaxoSmithKline, Genentech, British Biotech, Abgenix, Millennium, MorphoSys,
 Avalon, and Raven Biotechnologies.
 
      Contact:
      Mitchel Sayare, Ph.D.
      Chairman and CEO
      ImmunoGen, Inc.
      (617) 995-2500
      www.immunogen.com
 
 

SOURCE ImmunoGen, Inc.
    CAMBRIDGE, Mass., April 3 /PRNewswire/ --ImmunoGen, Inc. (Nasdaq:    IMGN)
 announced today that its presentation at Tucker Anthony Sutro's Health Care
 Conference 2001 will be webcast live.  The presentation will be delivered at
 1:40 p.m. (PST) on Wednesday, April 4, 2001, from the Ritz Carlton Hotel at
 Laguna Niguel, California.  The webcast can be accessed by going to the
 "Conference Schedule" page under "News/Events" on ImmunoGen's website at
 www.immunogen.com and will be available for one month following the
 presentation.
     ImmunoGen, Inc. develops innovative biopharmaceuticals, primarily for
 cancer treatment.  The Company has created potent tumor-activated prodrugs,
 consisting of drugs coupled to monoclonal antibodies, for delivery to and
 destruction of cancer cells.  Its lead product, huC242-DM1/SB-408075 is in two
 Phase I/II clinical trials for treatment of colorectal, pancreatic and certain
 non-small-cell lung cancers.  The Company has partnerships with
 GlaxoSmithKline, Genentech, British Biotech, Abgenix, Millennium, MorphoSys,
 Avalon, and Raven Biotechnologies.
 
      Contact:
      Mitchel Sayare, Ph.D.
      Chairman and CEO
      ImmunoGen, Inc.
      (617) 995-2500
      www.immunogen.com
 
 SOURCE  ImmunoGen, Inc.